Sana Biotechnology (NASDAQ:SANA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Sana Biotechnology (NASDAQ:SANA) issued its quarterly earnings data on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02, Zacks reports.

Sana Biotechnology Price Performance

SANA stock traded down $0.55 during trading on Tuesday, reaching $2.23. 4,178,711 shares of the stock traded hands, compared to its average volume of 2,988,203. Sana Biotechnology has a 52-week low of $1.52 and a 52-week high of $10.50. The business’s 50 day moving average price is $3.05 and its 200-day moving average price is $3.23. The firm has a market capitalization of $496.77 million, a PE ratio of -1.58 and a beta of 1.63.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SANA. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a report on Tuesday. Jefferies Financial Group assumed coverage on Sana Biotechnology in a report on Friday. They issued a “buy” rating and a $7.00 price target for the company. Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Tuesday. Finally, TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Insider Buying and Selling

In related news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 31.10% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.